Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A, Vasilică M, Coliţă A, Vasilache D, Dobrea C, Jardan C, Găman AM, Crişan AM, Coliţă D, Coriu D.
Rom J Morphol Embryol. 2013;54(4):1177-82.
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Gallì A, Travaglino E, Brisci A, Rumi E, Passamonti F, Invernizzi R, Cremonesi L, Boultwood J, Wainscoat JS, Hellström-Lindberg E, Cazzola M.
Blood. 2009 Oct 22;114(17):3538-45. doi: 10.1182/blood-2009-05-222331. Epub 2009 Aug 19.
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP.
Blood. 2006 Oct 1;108(7):2173-81. doi: 10.1182/blood-2006-02-005751. Epub 2006 Jun 1.
Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A, Abdel-Wahab O.
Int J Hematol. 2017 Jun;105(6):720-731. doi: 10.1007/s12185-017-2242-0. Epub 2017 May 2.
An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report.
Hao L, Sen S, Sugumar D.
Oncol Lett. 2015 Feb;9(2):749-751. doi: 10.3892/ol.2014.2754. Epub 2014 Dec 2.
Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM, Arenillas L, Domingo A, Bellosillo B, Gutiérrez G, Luño E, Piñán MA, Barbón M, Pérez-Sirvent ML, Muruzábal MJ, Yánez L, García L, Lemes A, Navarro JT, Elosegi A, Cortés MA, Villegas A, Durán MA, Ardanaz M, Florensa L; Grupo Español de Citología Hematológica (GECH), Working Group into the Asociación Española de Hematología y Hemoterapia (AEHH).
Int J Hematol. 2008 Nov;88(4):387-395. doi: 10.1007/s12185-008-0169-1. Epub 2008 Sep 27.
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S, Liu Q, Zhao W, Mehdi M, Galili N, Woda B, Raza A.
Leukemia. 2006 Sep;20(9):1641-4. doi: 10.1038/sj.leu.2404316. Epub 2006 Jul 27.
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC.
Haematologica. 2008 Jan;93(1):34-40. doi: 10.3324/haematol.11581.
Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.
Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, Sekeres MA, Maciejewski JP.
Am J Hematol. 2007 Dec;82(12):1076-9. doi: 10.1002/ajh.20995.
[Clinical and biological features in refractory anemia with ringed sideroblasts with fluctuant platelet counts].
Ji O, Shen Q, Lin L, Zhang YC, Ji JM, Wu Y, Chen JY, Zhu GR, Kong XT, Xia W, Jiang PJ.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):1036-41.
